Details of the FDA Form 483 that has loomed over Sun Pharma for the past two weeks have become public. Credit Suisse reports FDA inspectors made 23 observations during a recent inspection of a plant that accounts for up to 25% of Sun's sales, but the regulator found no evidence of data integrity failings.
When it comes to selling big, cancer drugs have a lot going for them. Their targets--deadly diseases that in many cases can kill quickly--put them in high demand, even as they continue to redefine "premium pricing." Some newer drugs can be targeted at patient groups who have the best chances of benefiting, helping justify those high costs. And biologics, for now, don't face the same generic onslaughts that pummel pharma sales come patent expiration time.
That's not to say they don't face roadblocks. Plenty of cancer heavyweights have run into failed label expansions, governmental cost critics, patent woes and biosimilar threats. But even so, the top 10 managed to rake in worldwide sales between $1.7 billion and $7.8 billion, according to EvaluatePharma data.
There has been talk in recent years about how the industry should expect fewer blockbusters and how drugmakers need to look toward selling more products for fewer dollars, euros, pounds or yen. But it is the big sellers, the blockbusters--no, megablockbusters--that drug execs aspire to develop. And a look at the top 10 best-selling drugs globally can't help but impress with its big numbers.
First of all, each of the top 10 best-selling drugs in the world knocked out more than $5.5 billion in sales last year, according to data provided by the market intelligence gurus at EvaluatePharma. Together, the top 10 turned in $76.38 billion in sales. Yes, that's more than $75 billion in sales from just 10 products. One other drug, Eli Lilly's Cymbalta, topped the $5 billion mark, but having lost its patent in December, it's headed for a serious nosedive this year.
POPULAR COMMENT THREADS
Consort Medical has placed a big bet on the convergence of drug and device production services, striking a £230 million ($374 million) deal to buy European contract manufacturer Aesica Pharmaceuticals.
The three-way spat between Health Canada, local media and Apotex is rumbling on. Late last week Health Canada won an equivocal thumbs-up from the media for its move to quarantine products from one of Apotex's Indian plants, only for the generic drugmaker to hit back with a press release to "set the record straight."
With a string of regulatory actions against manufacturers showing the dangers of relying heavily on one production plant, India's Strides Arcolab and Shasun Pharmaceuticals plan to merge to spread the risk.
The problem of contaminated cold remedies has once again surfaced in the U.S. More than seven years after diethylene glycol put authorities on high alert, a toddler in New York has suffered from lead poisoning after taking a Chinese cold remedy.
The Indian government has begun legal action against think tank the American Enterprise Institute (AEI) over a paper on drug quality, The Times of India reports.
Merck KGaA may have struggled getting new drug products to market, but its $17 billion buyout of Sigma-Aldrich will allow it to help others, as well as itself, in that endeavor.
From Our Sister Sites
The earliest awards from the U.S. National Institutes of Health in support of the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, totaling $46 million in fiscal 2014, have been disclosed. The funding goes to more than 100 investigators in 15 locations in the U.S. and three nations.
Investors were pleased that TransEnterix scored a few more quarters' worth of runway in a $25 million debt deal, sending shares up almost 7% in early trading. The minimally invasive surgical company expects to submit a 510(k) for its SurgiBot by year end.